Department of Medicine

Clinical trial to test HIV drugs to treat COVID-19

Vanderbilt University Medical Center, in collaboration with the University of Colorado and Beth Israel Deaconess Medical Center in Boston, is leading one of the first “telemedicine” clinical trials to test a potential treatment for COVID-19.

Possible COVID-19 “decoy”

It might be possible to use vesicles carrying the receptor for SARS-CoV-2, the virus that causes COVID-19, to bind the virus and prevent infection.

close up of blood vessels

Brain blood vessel response to hypoxia

The brain’s response to low oxygen — growth and remodeling of blood vessels — involves certain cell types and molecular pathways, Vanderbilt researchers have discovered.

Posing with the award presented by the Tennessee Hospital Association are (front row, from left) Molly Knostman, PharmD, MHA, C. Wright Pinson, MBA, MD, Patty Wright, MD, Mark Sullivan, PharmD (back row, from left) Halden Van Cleave, PharmD, MS, Deidra Dickerson, PharmD, Garrett Crothers, PharmD, Kevin Scharfman, PharmD, Eric Patton and Ryan Schell, PharmD.

THA honors VUMC efforts in remdesivir distribution

A team of pharmacists and physicians from Vanderbilt University Medical Center that this spring took on statewide distribution of remdesivir, an urgently needed investigational drug for severely ill patients hospitalized with COVID-19, has received the President’s Award from the Tennessee Hospital Association (THA).

COVID patient’s heart-lung transplant is world’s first

Vanderbilt University Medical Center has performed the world’s first dual heart-lung transplant of a COVID-19 patient.

Clue to diabetic kidney disease

Vanderbilt researchers have identified a signaling pathway that promotes kidney fibrosis in patients with diabetes — and that could be targeted with an existing approved medication.

1 44 45 46 47 48 102